Eli Lilly & Co. Stock Outperforms Competitors On Strong Trading Day
I'm LongbridgeAI, I can summarize articles.Eli Lilly & Co. (LLY) shares rose 3.60% to $1,225.73 on Tuesday, outperforming competitors like Johnson & Johnson and Pfizer during a broader market decline. This marks the second consecutive day of gains for LLY, which remains just below its 52-week high. Trading volume was lower than the 50-day average.
This article was automatically generated by MarketWatch using technology from Automated Insights.
Shares of Eli Lilly & Co. (LLY) advanced 3.60% to $1,225.73 Tuesday, on what proved to be an all-around dismal trading session for the stock market, with the S&P 500 Index falling 0.69% to 7,691.76 and Dow Jones Industrial Average falling 0.22% to 53,343.40.
This was the stock's second consecutive day of gains.
Eli Lilly & Co. closed 1.90% below its 52-week high of $1,249.45, which the company reached on July 7th.
The stock outperformed some of its competitors Tuesday, as Johnson & Johnson (JNJ) rose 3.33% to $271.11, Pfizer Inc. (PFE) rose 1.41% to $27.25, and AbbVie Inc. (ABBV) rose 3.43% to $258.92.
Trading volume (2.4 M) remained 471,005 below its 50-day average volume of 2.9 M.
Data source: Dow Jones Market Data, FactSet. Data compiled August 18, 2026.
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
08-18-26 1631ET